103 related articles for article (PubMed ID: 19204298)
1. Covalent JNK inhibitors?
Borhani DW
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):E18; author reply E19. PubMed ID: 19204298
[No Abstract] [Full Text] [Related]
2. Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor.
Bowers S; Truong AP; Neitz RJ; Neitzel M; Probst GD; Hom RK; Peterson B; Galemmo RA; Konradi AW; Sham HL; Tóth G; Pan H; Yao N; Artis DR; Brigham EF; Quinn KP; Sauer JM; Powell K; Ruslim L; Ren Z; Bard F; Yednock TA; Griswold-Prenner I
Bioorg Med Chem Lett; 2011 Mar; 21(6):1838-43. PubMed ID: 21316234
[TBL] [Abstract][Full Text] [Related]
3. Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity.
Chamberlain SD; Redman AM; Wilson JW; Deanda F; Shotwell JB; Gerding R; Lei H; Yang B; Stevens KL; Hassell AM; Shewchuk LM; Leesnitzer MA; Smith JL; Sabbatini P; Atkins C; Groy A; Rowand JL; Kumar R; Mook RA; Moorthy G; Patnaik S
Bioorg Med Chem Lett; 2009 Jan; 19(2):360-4. PubMed ID: 19071018
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Covalent MKK4/7 Dual Inhibitor.
Jiang J; Jiang B; He Z; Ficarro SB; Che J; Marto JA; Gao Y; Zhang T; Gray NS
Cell Chem Biol; 2020 Dec; 27(12):1553-1560.e8. PubMed ID: 32916088
[TBL] [Abstract][Full Text] [Related]
5. Modeling MEK4 Kinase Inhibitors through Perturbed Electrostatic Potential Charges.
Mishra RK; Deibler KK; Clutter MR; Vagadia PP; O'Connor M; Schiltz GE; Bergan R; Scheidt KA
J Chem Inf Model; 2019 Oct; 59(10):4460-4466. PubMed ID: 31566378
[TBL] [Abstract][Full Text] [Related]
6. Role of JNK and Contribution of p53 into Growth Potential of Mesenchymal Progenitor Cells In Vitro.
Zyuz'kov GN; Zhdanov VV; Udut EV; Miroshnichenko LA; Danilets MG; Simanina EV; Trofimova ES; Chaikovskii AV; Agafonov VI; Sherstoboev EY; Minakova MY; Burmina YV; Udut VV; Dygai AM
Bull Exp Biol Med; 2015 Jun; 159(2):245-7. PubMed ID: 26112108
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors.
Deibler KK; Schiltz GE; Clutter MR; Mishra RK; Vagadia PP; O'Connor M; George MD; Gordon R; Fowler G; Bergan R; Scheidt KA
ChemMedChem; 2019 Mar; 14(6):615-620. PubMed ID: 30707493
[TBL] [Abstract][Full Text] [Related]
9. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
[TBL] [Abstract][Full Text] [Related]
10. Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1',2':1,5]pyrazolo[3,4-d]pyrimidines.
Alberti MJ; Auten EP; Lackey KE; McDonald OB; Wood ER; Preugschat F; Cutler GJ; Kane-Carson L; Liu W; Jung DK
Bioorg Med Chem Lett; 2005 Aug; 15(16):3778-81. PubMed ID: 15993060
[TBL] [Abstract][Full Text] [Related]
11. A JUN N-terminal kinase inhibitor induces ectodomain shedding of the cancer-associated membrane protease Prss14/epithin via protein kinase CβII.
Yoon J; Cho Y; Kim KY; Yoon MJ; Lee HS; Jeon SD; Cho Y; Kim C; Kim MG
J Biol Chem; 2020 May; 295(20):7168-7177. PubMed ID: 32241917
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration.
Pfaffenrot B; Klövekorn P; Juchum M; Selig R; Albrecht W; Zender L; Laufer SA
Eur J Med Chem; 2021 Jun; 218():113371. PubMed ID: 33794385
[TBL] [Abstract][Full Text] [Related]
13. From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4).
Klövekorn P; Pfaffenrot B; Juchum M; Selig R; Albrecht W; Zender L; Laufer SA
Eur J Med Chem; 2021 Jan; 210():112963. PubMed ID: 33199152
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for producing selective MAP2K7 inhibitors.
Murakawa Y; Valter S; Barr H; London N; Kinoshita T
Bioorg Med Chem Lett; 2020 Nov; 30(22):127546. PubMed ID: 32931911
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of c-jun-N-terminal kinase (JNK).
LoGrasso P; Kamenecka T
Mini Rev Med Chem; 2008 Jul; 8(8):755-66. PubMed ID: 18673131
[TBL] [Abstract][Full Text] [Related]
16. Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.
Demetri GD
J Clin Invest; 2007 Dec; 117(12):3650-3. PubMed ID: 18060025
[TBL] [Abstract][Full Text] [Related]
17. Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
Wolle P; Hardick J; Cronin SJF; Engel J; Baumann M; Lategahn J; Penninger JM; Rauh D
J Med Chem; 2019 Mar; 62(5):2843-2848. PubMed ID: 30768270
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of JNK aggravates the recovery of rat hearts after global ischemia: the role of mitochondrial JNK.
Jang S; Javadov S
PLoS One; 2014; 9(11):e113526. PubMed ID: 25423094
[TBL] [Abstract][Full Text] [Related]
19. Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor.
Shraga A; Olshvang E; Davidzohn N; Khoshkenar P; Germain N; Shurrush K; Carvalho S; Avram L; Albeck S; Unger T; Lefker B; Subramanyam C; Hudkins RL; Mitchell A; Shulman Z; Kinoshita T; London N
Cell Chem Biol; 2019 Jan; 26(1):98-108.e5. PubMed ID: 30449673
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of JNK blockade as an early intervention treatment for type 1 diabetic nephropathy in hypertensive rats.
Lim AK; Ma FY; Nikolic-Paterson DJ; Ozols E; Young MJ; Bennett BL; Friedman GC; Tesch GH
Am J Nephrol; 2011; 34(4):337-46. PubMed ID: 21876346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
